BioAlpha Holdings

BioAlpha Holdings

Postby winston » Mon Sep 11, 2017 9:04 am

not vested

Stock on Radar - HLIB Retail Research
Trading Buy: BIOHLDG - 0179
(Last price: RM0.255, Potential upside +19.6%)

Company Profile

Listed in Apr 2015, BIOHLDG is a home-grown integrated health supplements company, producing a variety of health supplements in herbal and non-herbal (halal & non-halal) based. About 60% of group revenue is from house brands and its best sellers include tiger milk mushroom, cordyceps sinensis, tongkat ali and collagen beauty products

Trading Catalyst
Trading at cheap 10.3x P/E18 (ex-cash), BIOHLDG is an up-and-coming integrated health supplement group with strong inhouse R&D, supported by upstream into farming as well as downstream into retail pharmacy.
Tapping into strong regional markets growth in China and Indonesia.
Positive for a triangle breakout to test RM0.285-0.305 levels.

Technical View
Resistance: RM0.270 / RM0.285 / RM0.305
Support: RM0.245 / RM0.240
Cut loss: RM0.235

Key Financial Stats
Trading at 10.3x FY18 P/E (ex-cash), 31% below peers
Strong EPS CAGR of 37% from FY16-19.

Source: Bloomberg, HLIB
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118523
Joined: Wed May 07, 2008 9:28 am

Re: BioAlpha Holdings

Postby winston » Mon Sep 11, 2017 9:11 am

not vested

CIMB Research retains target price of 37 sen for Bioalpha

KUALA LUMPUR: CIMB Equities Research is maintaining its earnings per share (EPS) forecasts and target price of 37 sen for Bioalpha Holdings, an integrated health supplement company.

It said on Monday the target price was based on 20 times FY18F price-to-earnings (P/E) which is at a 20% discount to its 25 times CY18F target P/E for the consumer sector.

“The discount reflects Bioalpha’s small market cap. The stock remains an Add and potential catalysts include stronger-than-expected sales from China and India, its two main export markets. A downside risk is weak domestic sales,” it said.

CIMB Research said on Sept 6, Bioalpha organised a site visit for fund managers and analysts to the Pasir Raja Herbal Park (PRHP) in Terengganu. Bioalpha also has another 295 acres of herbal park land in Kota Tinggi, Johor.

In 2014, Bioalpha was appointed by East Coast Economic Region Development Council (ECERDC) as the anchor company to develop the 1,004 acre PRHP land into an integrated herbal cluster and manage it.

Bioalpha expects PRHP to help the company source its own herbs and improve its quality control.

So far, 124 acres of PRHP land have been cleared and planted with various herbs such as Kacip Fatimah, Tongkat Ali, Roselle, ginger, lemongrass, papaya, coconut and black pepper.

While it may only take one year for a papaya tree to mature, it takes five to seven years for coconut trees and Tongkat Ali plants.

“We estimate the current average selling price (ASP) of raw materials from PRHP is around RM3 a kg and we expect ASP to gradually rise as the plantation matures over the next few years.

“Bioalpha targets production of only 200 tonnes of raw materials from PRHP in 2017F. Assuming ASP of RM3 a kg, we estimate revenue from PRHP this year would be only RM600,000 and pretax profit (PBT) of RM300,000 (assuming 50% PBT margin).

“However, by 2020F, PRHP production could rise to c.2,000 tonnes per annum. and assuming a conservative ASP of RM3 a kg, we project PRHP revenue of RM6mil and PBT of RM3mil (50% PBT margin). We have not assumed any earnings from PRHP in our earnings forecasts,” it said.

As it takes seven years for the Tongkat Ali plant to mature, Bioalpha currently sources its Tongkat Ali root from the Orang Asli who gather the roots from the jungle.

“We estimate Bioalpha would start to source its Tongkat Ali root internally in 2020F onwards. We understand there could soon be an industry shortage of Tongkat Ali as distributors from China have been purchasing Tongkat Ali in large quantities over the past few years. This could be long-term positive for herbal planters like Bioalpha,” said CIMB Research.

Source: The Star

http://www.thestar.com.my/business/busi ... -bioalpha/

https://brokingrfs.cimb.com/Jlbr-XD667y ... BUiaA2.pdf
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118523
Joined: Wed May 07, 2008 9:28 am

Re: BioAlpha Holdings

Postby winston » Mon Oct 22, 2018 8:59 am

not vested

Trading Buy: BIOHLDG - 0179
(Last price: RM0.255, Potential upside +31.4%)

Company Profile
• BIOHLDG is involved in the manufacture and sale of health supplement products.

Trading Catalyst

• BIOHLDG has grown to become an integrated biotechnology company with businesses comprising all segments of the supply chain (eg in-house cultivation of raw materials, R&D, ODM, distribution and pharmacy chains).

• Valuations are undemanding at 9.6x FY19 P/E and 1.5x P/B (34% and 20% lower than its bigger cap peers). More synergies are coming from the recent proposed NWE’s acquisition to distribute its products to hotels all across the country as well as the MOU with Jinrui Fortune Group, China to jointly develop “Thousand Medicinal Hall” platform and herbal farms in China.

• Following the weekly bullish LT downtrend line breakout and double bottom formation, we expect more upside to RM0.30-0.335 pending a flag breakout.

Technical View
• Resistance: RM0.275 / RM0.300 / RM0.335
• Support: RM0.245 / RM0.225
• Cut loss: RM0.215

Key Financial Stats
• Trading at 9.6x FY19E P/E (34% below peers)
• Trading at 1.5x P/B (20% below peers)

Source: HLIB
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118523
Joined: Wed May 07, 2008 9:28 am


Return to A to D

Who is online

Users browsing this forum: No registered users and 7 guests